Cencora’s $2.4 Billion American Oncology Network Deal Pushes Deeper Into Cancer Care
Cencora’s $2.4 billion acquisition of American Oncology Network marks a strategic move from drug distribution into direct cancer-care provision.
Jemperli’s Accelerated FDA Approval Could Expand AnaptysBio’s Royalty Opportunity
Jemperli’s expanded FDA approval could strengthen AnaptysBio’s royalty opportunity while limiting it…
Alcon’s Neurotech Acquisition Deepens Its Push Into Ophthalmic Pharmaceuticals
Alcon’s acquisition of Neurotech Pharmaceuticals could broaden its ophthalmic drug pipeline and expa…
Cencora’s $2.4 Billion Oncology Acquisition Tests the Case for Vertical Integration
Cencora’s $2.4 billion American Oncology Network deal expands its role from drug distribution into o…
Myriad’s $210 Million Prenatal Exit Gives Labcorp a Larger Genetic Testing Footprint
Myriad Genetics agreed to sell its prenatal health testing business to Labcorp for $210 million, str…
Novo Nordisk’s CagriSema Delivers 25% Weight Loss in Women, Raising Stakes in the GLP-1 Market
Novo Nordisk’s CagriSema produced 25% weight loss in women in a late-stage analysis, sharpening focu…
Ultragenyx Stock Plunges More Than 40% After Angelman Syndrome Drug Fails Phase III Trial
Ultragenyx shares plunged more than 40% after apazunersen failed both primary and secondary endpoint…
Ultragenyx Shares Sink More Than 40% After Apazunersen Fails Phase 3 Trial
Ultragenyx shares fell more than 40% after apazunersen failed both Phase 3 endpoints, spotlighting b…
Rare-Disease Biotech Stocks Gain Focus After Protagonist’s $275 Million Milestone and Agios Phase 3 Data
A $275 million Protagonist milestone and Agios’ mixed Phase 3 RISE UP data put rare blood-disease ca…
Novo Nordisk’s CagriSema Delivers 25% Weight Loss in Women as GLP-1 Race Intensifies
CagriSema’s 25% weight-loss result could strengthen Novo Nordisk’s growth narrative as competition w…